300254 Stock Overview
Engages in the research, development, production, and sale of medicine and health food products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ShanXi C&Y Pharmaceutical Group Co.,LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.43 |
| 52 Week High | CN¥11.86 |
| 52 Week Low | CN¥4.98 |
| Beta | 0.25 |
| 11 Month Change | -5.51% |
| 3 Month Change | 17.88% |
| 1 Year Change | -10.19% |
| 33 Year Change | 39.50% |
| 5 Year Change | 21.83% |
| Change since IPO | -19.27% |
Recent News & Updates
Recent updates
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet
Sep 30
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06Shareholder Returns
| 300254 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.1% | 0.3% | -0.6% |
| 1Y | -10.2% | -7.9% | 3.2% |
Return vs Industry: 300254 underperformed the CN Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 300254 underperformed the CN Market which returned 3.2% over the past year.
Price Volatility
| 300254 volatility | |
|---|---|
| 300254 Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300254 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300254's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,234 | Qun Zhao | www.cy-pharm.com |
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It offers anti-infective drugs, anti-allergic drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, antidepressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Mezlocillin sodium sulbactam sodium for injection, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Flouxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Smectite powder, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as provides DNA gene preservation services.
ShanXi C&Y Pharmaceutical Group Co.,LTD. Fundamentals Summary
| 300254 fundamental statistics | |
|---|---|
| Market cap | CN¥2.34b |
| Earnings (TTM) | CN¥83.04m |
| Revenue (TTM) | CN¥836.18m |
28.2x
P/E Ratio2.8x
P/S RatioIs 300254 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300254 income statement (TTM) | |
|---|---|
| Revenue | CN¥836.18m |
| Cost of Revenue | CN¥275.04m |
| Gross Profit | CN¥561.14m |
| Other Expenses | CN¥478.10m |
| Earnings | CN¥83.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.33 |
| Gross Margin | 67.11% |
| Net Profit Margin | 9.93% |
| Debt/Equity Ratio | 14.8% |
How did 300254 perform over the long term?
See historical performance and comparison